Dr. Vaishnavi brings over 20 years of expertise in neuroscience, clinical psychiatry, and research to his role as Medical Director at Cognitive Research Corporation. He specializes in ADHD, major depressive disorder, PTSD, and Alzheimer’s disease, having made significant contributions to several pivotal clinical trials. His work includes serving as a principal investigator for trials that resulted in FDA approval for Rexulti for Alzheimer’s disease-related agitation, and trials supporting the FDA clearance of Rejoyn as an adjunct treatment for MDD and EndeavorRx for ADHD in children, adolescents, and adults. Additionally, Dr. Vaishnavi has conducted groundbreaking research in transcranial magnetic stimulation (TMS) for PTSD, including an ongoing EEG-guided TMS study.  

Dr. Vaishnavi holds a Ph.D. in Cognitive Science with a focus on cognitive neuroscience from the University of Alabama at Birmingham (UAB), were he also did his M.D.  He did his residency in Psychiatry at Duke University, where he also completed the Duke-GlaxoSmithKline Clinical Psychopharmacology Fellowship Program. He has completed a fellowship in Behavioral Neurology & Neuropsychiatry from Johns Hopkins.  He is a Fellow of the American Neuropsychiatric Association, nominated to and a member of the Sigma Xi Scientific Honor Society, and a Castle Connolly Best Doctor (2024). Additionally, Dr. Vaishnavi has authored more than 55 peer-reviewed papers and scientific abstracts, contributing to high-impact journals including JAMA Network Open, American Journal of Psychiatry, and Biological Psychiatry.  

Dr. Vaishnavi is certified in Psychiatry by the American Board of Psychiatry and Neurology, and in Behavioral Neurology & Neuropsychiatry by the United Council for Neurologic Subspecialties. At CRC, he leverages his expertise to guide clinical trial strategies, ensuring the delivery of high-quality data to advance CNS treatments. His dedication to improving patient outcomes through innovative research makes him an invaluable asset to CRC.